These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 8579804)

  • 1. Single photon emission tomography (SPET) imaging of dopamine D2 receptors in the course of dopamine replacement therapy in patients with nocturnal myoclonus syndrome (NMS).
    Staedt J; Stoppe G; Kögler A; Riemann H; Hajak G; Munz DL; Emrich D; Rüther E
    J Neural Transm Gen Sect; 1995; 99(1-3):187-93. PubMed ID: 8579804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nocturnal myoclonus syndrome (periodic movements in sleep) related to central dopamine D2-receptor alteration.
    Staedt J; Stoppe G; Kögler A; Riemann H; Hajak G; Munz DL; Emrich D; Rüther E
    Eur Arch Psychiatry Clin Neurosci; 1995; 245(1):8-10. PubMed ID: 7786913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dopamine D2 receptor alteration in patients with periodic movements in sleep (nocturnal myoclonus).
    Staedt J; Stoppe G; Kögler A; Munz D; Riemann H; Emrich D; Rüther E
    J Neural Transm Gen Sect; 1993; 93(1):71-4. PubMed ID: 8103994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of iodine-123 epidepride and iodine-123 IBZM for dopamine D2 receptor imaging in clinically non-functioning pituitary macroadenomas and macroprolactinomas.
    de Herder WW; Reijs AE; de Swart J; Kaandorp Y; Lamberts SW; Krenning EP; Kwekkeboom DJ
    Eur J Nucl Med; 1999 Jan; 26(1):46-50. PubMed ID: 9933661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [123I]IBZM SPET analysis of dopamine D2 receptor occupancy in narcoleptic patients in the course of treatment.
    Staedt J; Stoppe G; Kögler A; Riemann H; Hajak G; Rodenbeck A; Mayer G; Steinhoff BJ; Munz DL; Emrich D; Rüther E
    Biol Psychiatry; 1996 Jan; 39(2):107-11. PubMed ID: 8717608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of [123I]IBZM pinhole SPECT for the detection of striatal dopamine D2 receptor availability in rats.
    Scherfler C; Scholz SW; Donnemiller E; Decristoforo C; Oberladstätter M; Stefanova N; Diederen E; Virgolini I; Poewe W; Wenning GK
    Neuroimage; 2005 Feb; 24(3):822-31. PubMed ID: 15652317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolism of [123I]epidepride may affect brain dopamine D2 receptor imaging with single-photon emission tomography.
    Bergström KA; Yu M; Kuikka JT; Akerman KK; Hiltunen J; Lehtonen J; Halldin C; Tiihonen J
    Eur J Nucl Med; 2000 Feb; 27(2):206-8. PubMed ID: 10755727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple system atrophy and progressive supranuclear palsy. Diminished striatal D2 dopamine receptor activity demonstrated by 123I-IBZM single photon emission computed tomography.
    van Royen E; Verhoeff NF; Speelman JD; Wolters EC; Kuiper MA; Janssen AG
    Arch Neurol; 1993 May; 50(5):513-6. PubMed ID: 8489409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo imaging of pituitary tumours using a radiolabelled dopamine D2 receptor radioligand.
    de Herder WW; Reijs AE; Kwekkeboom DJ; Hofland LJ; Nobels FR; Oei HY; Krenning EP; Lamberts SW
    Clin Endocrinol (Oxf); 1996 Dec; 45(6):755-67. PubMed ID: 9039343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [123]IBZM binding predicts dopaminergic responsiveness in patients with parkinsonism and previous dopaminomimetic therapy.
    Schwarz J; Tatsch K; Gasser T; Arnold G; Oertel WH
    Mov Disord; 1997 Nov; 12(6):898-902. PubMed ID: 9399212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced striatal dopamine transporters in idiopathic rapid eye movement sleep behaviour disorder. Comparison with Parkinson's disease and controls.
    Eisensehr I; Linke R; Noachtar S; Schwarz J; Gildehaus FJ; Tatsch K
    Brain; 2000 Jun; 123 ( Pt 6)():1155-60. PubMed ID: 10825354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo measurement of haloperidol affinity to dopamine D2/D3 receptors by [123I]IBZM and single photon emission computed tomography.
    Videbaek C; Toska K; Friberg L; Holm S; Angelo HR; Knudsen GM
    J Cereb Blood Flow Metab; 2001 Jan; 21(1):92-7. PubMed ID: 11149673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. D2-receptor imaging with [123I]IBZM and single photon emission tomography in psychiatry: a survey of current status.
    Schlösser R; Schlegel S
    J Neural Transm Gen Sect; 1995; 99(1-3):173-85. PubMed ID: 8579803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [In vivo characteristics of IBZM in rat brains: an agent for quantitative SPECT imaging of dopamine D2 receptors. Preparation of 125I-IBZM and its biodistribution and kinetic properties].
    Matsumura K; Toyama H; Nakashima H; Ichise M; Kurami M; Nakagawa T; Maeda H; Takeuchi A; Koga S
    Kaku Igaku; 1994 May; 31(5):513-9. PubMed ID: 8028224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis, in vitro binding profile and biodistribution of a 125I-labeled N-benzyl pyrrolidinyl benzamide derivative: a potential radioligand for mapping dopamine D2 receptors.
    Saji H; Tanahashi K; Kinoshita T; Iida Y; Magata Y; Yokoyama A
    Nucl Med Biol; 1996 Feb; 23(2):121-7. PubMed ID: 8868283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and in vivo D2-dopamine receptor binding with [123I]S(-) iodobenzamide ([123I]IBZM) in rat and human brain.
    Verhoeff NP; Bobeldijk M; Feenstra MG; Boer GJ; Maas MA; Erdtsieck-Ernste E; de Bruin K; van Royen EA
    Int J Rad Appl Instrum B; 1991; 18(8):837-46. PubMed ID: 1839302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The determination of cerebral dopamine (D2) receptor density by using 123I-IBZM-SPECT in Parkinson disease patients].
    Hierholzer J; Cordes M; Schelosky L; Barzen G; Poewe W; Henkes H; Keske U; Horowski R; Felix R
    Rofo; 1992 Oct; 157(4):390-8. PubMed ID: 1391843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Iodine-123-iodobenzamide binding in parkinsonism: reduction by dopamine agonists but not L-Dopa.
    Schwarz J; Oertel WH; Tatsch K
    J Nucl Med; 1996 Jul; 37(7):1112-5. PubMed ID: 8965179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alterations of striatal dopamine D2 receptors contribute to deteriorated response to L-dopa in Parkinson's disease: a [123I]-IBZM SPET study.
    Pizzolato G; Chierichetti F; Rossato A; Cagnin A; Fabbri M; Dam M; Ferlin G; Battistin L
    J Neural Transm Suppl; 1995; 45():113-22. PubMed ID: 8748616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Striatal and temporal cortical D2/D3 receptor occupancy by olanzapine and sertindole in vivo: a [123I]epidepride single photon emission tomography (SPET) study.
    Bigliani V; Mulligan RS; Acton PD; Ohlsen RI; Pike VW; Ell PJ; Gacinovic S; Kerwin RW; Pilowsky LS
    Psychopharmacology (Berl); 2000 Jun; 150(2):132-40. PubMed ID: 10907666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.